PL3200815T3 - Sposoby i kompozycje do leczenia nowotworu - Google Patents

Sposoby i kompozycje do leczenia nowotworu

Info

Publication number
PL3200815T3
PL3200815T3 PL15847792T PL15847792T PL3200815T3 PL 3200815 T3 PL3200815 T3 PL 3200815T3 PL 15847792 T PL15847792 T PL 15847792T PL 15847792 T PL15847792 T PL 15847792T PL 3200815 T3 PL3200815 T3 PL 3200815T3
Authority
PL
Poland
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
PL15847792T
Other languages
English (en)
Inventor
Alfredo PERALES-PUCHALT
Jose R. Conejo-Garcia
Original Assignee
The Wistar Institute Of Anatomy And Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute Of Anatomy And Biology filed Critical The Wistar Institute Of Anatomy And Biology
Publication of PL3200815T3 publication Critical patent/PL3200815T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15847792T 2014-10-02 2015-09-30 Sposoby i kompozycje do leczenia nowotworu PL3200815T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462059068P 2014-10-02 2014-10-02
US201562202824P 2015-08-08 2015-08-08
PCT/US2015/053128 WO2016054153A1 (en) 2014-10-02 2015-09-30 Methods and compositions for treating cancer
EP15847792.7A EP3200815B1 (en) 2014-10-02 2015-09-30 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
PL3200815T3 true PL3200815T3 (pl) 2021-10-18

Family

ID=55631412

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15847792T PL3200815T3 (pl) 2014-10-02 2015-09-30 Sposoby i kompozycje do leczenia nowotworu

Country Status (15)

Country Link
US (3) US10259855B2 (pl)
EP (1) EP3200815B1 (pl)
CN (2) CN114150018A (pl)
CA (1) CA2989807C (pl)
CY (1) CY1125797T1 (pl)
DK (1) DK3200815T3 (pl)
ES (1) ES2870607T3 (pl)
HR (1) HRP20210705T1 (pl)
HU (1) HUE054673T2 (pl)
LT (1) LT3200815T (pl)
PL (1) PL3200815T3 (pl)
PT (1) PT3200815T (pl)
RS (1) RS61929B1 (pl)
SI (1) SI3200815T1 (pl)
WO (1) WO2016054153A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538568B2 (en) * 2014-11-04 2020-01-21 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor
JP2019510786A (ja) * 2016-04-05 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫療法におけるＴＧＦβの阻害
IT201600101852A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
WO2018069831A2 (en) * 2016-10-11 2018-04-19 Abresearch S.R.L. Ligands of the fsh hormone receptor in the diagnosis and treatment of tumors
IT201600101870A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
US11786557B2 (en) 2017-10-02 2023-10-17 Fred Hutchinson Cancer Center Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
WO2019136288A1 (en) * 2018-01-05 2019-07-11 Maxcyte, Inc. Chronic car treatment for cancer
US20210403546A1 (en) * 2018-11-05 2021-12-30 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
WO2020146233A1 (en) * 2019-01-07 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Foxp1-ablated chimeric cells
BR112021014255A2 (pt) * 2019-01-30 2022-01-18 Wistar Inst Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio
CA3136626A1 (en) * 2019-04-12 2020-10-15 Emory University Compositions and methods for promoting hematopoietic cell cytotoxicity
WO2021168421A1 (en) * 2020-02-20 2021-08-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
US20240101626A1 (en) * 2021-02-12 2024-03-28 Kar Muthumani Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
CN115975056B (zh) * 2023-02-07 2023-12-01 徐州医科大学 利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702702A (en) 1992-03-30 1997-12-30 The Wistar Institute Of Anatomy And Biology Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2003270063A1 (en) 2002-09-04 2004-03-29 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
EP2000160A3 (en) 2002-10-30 2009-03-11 Gambro Lundia AB Method and apparatuses for determining the efficiency of dialysis
CA2880061C (en) 2004-01-23 2018-03-13 Agostino Cirillo Chimpanzee adenovirus vaccine carriers
EP1844145A2 (en) 2005-02-03 2007-10-17 Benitec, Inc. Rnai expression constructs
GB0725201D0 (en) 2007-12-24 2008-01-30 Asterion Ltd Peptide fusion proteins
AU2009206212B2 (en) 2008-01-24 2014-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
EP2090322A1 (en) 2008-02-18 2009-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fsh receptor ligands for diagnosis and therapy of cancer
RU2744176C2 (ru) * 2008-12-19 2021-03-03 Макродженикс, Инк. Ковалентные диантитела и их применение
SG190997A1 (en) * 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
WO2013063019A1 (en) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
EP2920212A4 (en) * 2012-11-15 2016-07-27 Esperance Pharmaceuticals Inc FUSION CONSTRUCTS FROM FOLLICULAR STIMULATING HORMONE (FSH) AND A LYTIC DOMAIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
CN103509121B (zh) * 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
US10538568B2 (en) 2014-11-04 2020-01-21 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor

Also Published As

Publication number Publication date
CN106999552B (zh) 2021-12-28
HRP20210705T1 (hr) 2021-07-23
EP3200815B1 (en) 2021-03-03
LT3200815T (lt) 2021-07-26
US11248033B2 (en) 2022-02-15
PT3200815T (pt) 2021-05-07
SI3200815T1 (sl) 2021-11-30
CN106999552A (zh) 2017-08-01
US20220185861A1 (en) 2022-06-16
CN114150018A (zh) 2022-03-08
ES2870607T3 (es) 2021-10-27
US20190248862A1 (en) 2019-08-15
WO2016054153A1 (en) 2016-04-07
DK3200815T3 (da) 2021-05-10
US20170226176A1 (en) 2017-08-10
CY1125797T1 (el) 2024-02-16
RS61929B1 (sr) 2021-06-30
CA2989807A1 (en) 2016-04-07
US10259855B2 (en) 2019-04-16
EP3200815A1 (en) 2017-08-09
EP3200815A4 (en) 2018-04-25
HUE054673T2 (hu) 2021-09-28
CA2989807C (en) 2023-07-04

Similar Documents

Publication Publication Date Title
IL267247B (en) Compositions and methods for treating cancer
IL304820A (en) Preparations and methods for the treatment of cancer
EP3507304C0 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DUOCARS
HK1251862A1 (zh) 治療癌症的方法和組合物
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
PT3377516T (pt) Composição para o tratamento do cancro
SG11201700079VA (en) Combination therapy compositions and methods for treating cancers
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
IL251759A0 (en) Preparations and methods for treating insomnia
IL256523A (en) Compositions and methods for treating cancer
IL246558A0 (en) New methods of cancer treatment
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER
EP3154544A4 (en) Compositions and methods for treating cancers
ZA201605109B (en) Compositions and methods for treating neutropenia
IL255638A (en) Compositions and methods for treating cancer
ZA201703771B (en) Compositions and methods for treating hyperkalemia
ZA201802268B (en) Methods and compositions for preventing or treating cancer
EP3268028A4 (en) Compositions and methods for treating cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
EP3160591A4 (en) Compositions and methods for treating cancer
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201414904D0 (en) Materials and methods for treating cancer